Genmab — Februar 2024

[Bulder]

Genmab is not to be blamed for the current Price. It’s not Long ago it was +3000. Business hasn’t changed since then.

[JørgenVarnæs]

No? I beg to differ

[JørgenVarnæs]

When Verdult says he still has respect for GEN leadership - but dara has been gifted to the partner and hexacd38 is closed country, he is really saying - there is not much respect left

[E_L]

GEN1046 Safety Trial has gone from Recruiting -to - Active, not recruiting https://classic.clinicaltrials.gov/ct2/history/NCT03917381?A=26&B=27&C=merged#StudyPageTop

[Teller]

To be honest - My greatest concern is the deal made on super Dara. Was the same lawyers used for this deal??

[w]

i asked Carlsen about this, regarding a sub version

[w]

Hi Martin,
Hexabody CD38 is currently intravenous but can be made to SC by JnJ

[Teller]

You not only have to be a good scientist and be able to develop new and wonderful drugs. You also and importantly have to be extremely "Street-smart" in a legal sense.

[gdn55]

Er dette ikke en dansk chat?

[Bulder]

Sc hex 38 er i hvert fald et nyt statement. Winkel er blevet spurgt flere gange, og sagt, at det var for tidligt at afgøre.

[KWC]

Konkurence ? https://www.biospace.com/article/gsk-s-blenrep-scores-phase-iii-win-in-multiple-myeloma/?utm_campaign=Daily Social | News&utm_content=281354534&utm_medium=social&utm_source=facebook&hss_channel=fbp-10530620221

[KWC]

GSK’s Blenrep Combo Scores Phase III Win in Multiple Myeloma

[Bulder]

En vis konkurrence - i 2. linje. 1/3 får grad 3 eller værre problemer med synet.

[Helge_LarsenPI-redaktør]

Godmorgen

[Plimsoller]

God morgen

[Stroka]

God morgen

[LP90]

God morgen

[E_L]

AMGEN: TEPEZZA (teprotumumab-trbw) generated $448 million of sales for the period. TEPEZZA is the first and only FDA-approved treatment for thyroid eye disease (TED). -Sales figures reflect only sales in the period from Oct. 6 2023 through the end of the year, and not the full quarter. https://investors.amgen.com/news-releases/news-release-details/amgen-reports-fourth-quarter-and-full-year-2023-financial

[E_L]

In December 2023, TEPEZZA received orphan drug designation in Japan for patients with moderate to severe active thyroid eye disease (TED).
A New Drug Application was submitted for TEPEZZA in Japan based on the results from the OPTIC-J study evaluating TEPEZZA in patients with active TED.
A Phase 3 study of TEPEZZA in Japan for chronic or low clinical activity score (CAS) TED continues to enroll patients.

[E_L]

The Company plans to initiate a Phase 3 study evaluating the subcutaneous route of administration of TEPEZZA in patients with TED in H1 2024.